Factor XIII Level at Lahore PCR Lab

Factor XIII Level at Lahore PCR Lab

Factor XIII (FXIII), historically known as fibrin stabilizing factor, is a crucial enzyme of the human coagulation cascade. Unlike most other coagulation factors which are serine proteases, Factor XIII is a protransglutaminase. It plays a vital role at the final stage of blood clotting by catalyzing the formation of covalent bonds between fibrin monomers. This cross-linking process transforms a weak, soluble, and unstable fibrin clot into a highly stable, insoluble physical barrier that can resist premature degradation (fibrinolysis). Lahore PCR Lab, located in Lahore, Pakistan, provides high-precision quantitative Factor XIII Level testing to assist clinicians in diagnosing rare bleeding disorders, investigating delayed wound healing, and managing recurrent pregnancy complications.

The clinical importance of Factor XIII cannot be overstated. Standard routine coagulation screening tests, including Prothrombin Time (PT), Activated Partial Thromboplastin Time (aPTT), Thrombin Time (TT), and bleeding time, are completely blind to Factor XIII deficiency. This is because these routine tests only measure the time it takes to form the initial, soluble fibrin gel, a process that occurs before Factor XIII is activated. Consequently, a patient with a severe, life-threatening Factor XIII deficiency will typically present with completely normal routine coagulation profiles. The quantitative Factor XIII assay performed at Lahore PCR Lab is the definitive diagnostic tool required to identify this specific deficiency, ensuring that patients receive timely, life-saving therapy such as Factor XIII concentrates or fresh frozen plasma.

At Lahore PCR Lab, advanced automated coagulation analyzers and chromogenic activity assays are utilized to determine the exact functional activity of Factor XIII in the patient's plasma. This state-of-the-art technology ensures maximum diagnostic sensitivity and specificity. The test evaluates the catalytic activity of the enzyme, allowing hematologists to distinguish between congenital deficiencies (which are rare autosomal recessive disorders) and acquired deficiencies, which can arise due to autoantibodies, severe liver disease, inflammatory bowel disease, or consumption in conditions like Disseminated Intravascular Coagulation (DIC).

Clinical Procedure: What to Expect

Patient Preparation

Proper patient preparation is essential to ensure the clinical accuracy of specialized coagulation assays like the Factor XIII Level test. Patients undergoing this test at Lahore PCR Lab should adhere to the following preparation guidelines:

• Medication Disclosure: Patients must inform their physician and the laboratory staff of all medications they are currently taking, particularly anticoagulants such as heparin, warfarin, or direct oral anticoagulants (DOACs), as well as any recent administration of plasma products or Factor XIII concentrates.
• Fasting Requirements: While strict fasting is not universally mandatory for a Factor XIII test, a light fast of 4 to 6 hours is highly recommended to prevent lipemia in the blood sample, which can interfere with optical and chromogenic assay measurements.
• Hydration: Adequate hydration with plain water is encouraged prior to the blood draw to facilitate easy venous access and ensure a smooth venipuncture process.
• Avoid Strenuous Exercise: Patients should avoid vigorous physical activity for at least 12 hours before the test, as extreme physical exertion can temporarily alter coagulation factor levels and plasma volume.
• Timing of the Test: If the test is being performed to monitor the efficacy of Factor XIII replacement therapy, the blood sample should be drawn at the specific trough or peak times designated by the treating hematologist.

During the Procedure

The collection of a blood sample for a Factor XIII Level test at Lahore PCR Lab follows strict clinical protocols to prevent pre-analytical errors that could compromise the test results:

• Patient Positioning: The patient is comfortably seated or placed in a recumbent position. The phlebotomist will identify a suitable vein, typically in the antecubital fossa of the arm.
• Aseptic Technique: The skin over the selected vein is thoroughly cleansed with an antiseptic solution (such as 70% isopropyl alcohol) and allowed to air dry completely to prevent hemolysis.
• Venipuncture and Sample Collection: A sterile, single-use needle is inserted into the vein. The blood is collected directly into a light blue-top tube containing 3.2% buffered sodium citrate as an anticoagulant. The ratio of blood to anticoagulant (9:1) must be precise to ensure accurate results.
• Gentle Mixing: Immediately after collection, the tube is gently inverted 3 to 4 times to mix the blood thoroughly with the sodium citrate anticoagulant, preventing micro-clot formation. The tube must never be shaken vigorously.
• Duration and Safety: The entire venipuncture procedure takes less than five minutes. It is a minimally invasive procedure with negligible risks, though mild bruising or transient discomfort at the puncture site may occur.
• Specimen Processing: The sample is promptly delivered to the laboratory department, where it undergoes double centrifugation at controlled temperatures to obtain platelet-poor plasma (PPP), which is essential for accurate coagulation testing.

When is a Factor XIII Level Test Performed?

Unexplained Bleeding with Normal Screening Profiles

Physicians request a Factor XIII Level test when a patient exhibits significant clinical bleeding symptoms—such as easy bruising, mucosal bleeding, or excessive post-traumatic hemorrhage—but routine coagulation screens (PT, aPTT, INR, and platelet counts) return completely normal results. Because Factor XIII operates at the very end of the clotting cascade, its absence does not affect the clotting times measured by standard assays. Identifying a low Factor XIII level in these patients is critical to establishing a correct diagnosis and preventing catastrophic bleeding episodes.

Delayed Post-Traumatic or Post-Surgical Hemorrhage

A classic clinical hallmark of Factor XIII deficiency is delayed bleeding. Following trauma, dental extraction, or surgical procedures, the patient's primary and secondary hemostatic mechanisms work normally to form an initial, temporary clot, which temporarily stops the bleeding. However, because the clot lacks the covalent cross-linking provided by Factor XIII, it is highly susceptible to premature enzymatic breakdown by the fibrinolytic system. As a result, severe bleeding typically recurs 24 to 36 hours after the initial insult. A Factor XIII Level test is performed to confirm this specific pathological mechanism.

Delayed Umbilical Cord Bleeding in Newborns

In cases of congenital Factor XIII deficiency, umbilical cord bleeding is one of the earliest and most characteristic clinical presentations, occurring in up to 80% of affected newborns. Bleeding from the umbilical stump typically begins several days after birth, rather than immediately. Pediatricians and neonatologists in Lahore promptly order a Factor XIII Level test when a neonate presents with persistent, unexplained oozing or frank hemorrhage from the umbilical site, as early diagnosis and prophylactic replacement therapy are life-saving.

Recurrent Spontaneous Abortions and Pregnancy Loss

Factor XIII is highly expressed in the placenta, where it is essential for the stabilization of the placental-uterine attachment and the normal development of the cytotrophoblast. Women with severe congenital or acquired Factor XIII deficiency frequently experience recurrent spontaneous abortions, typically during the first trimester of pregnancy. Obstetricians and fertility specialists request this test as part of a comprehensive workup for recurrent pregnancy loss, as maintaining adequate Factor XIII levels through targeted replacement therapy can enable successful full-term pregnancies.

Poor or Delayed Wound Healing

Beyond its role in hemostasis, Factor XIII plays an indispensable role in tissue repair and wound healing. It cross-links fibrin with extracellular matrix proteins, such as fibronectin and collagen, which provides a structural scaffold for migrating fibroblasts and inflammatory cells during the proliferative phase of healing. Patients with low Factor XIII levels often present with chronic, non-healing wounds, abnormal scar formation, or wound dehiscence after surgical procedures. Evaluating Factor XIII levels helps wound care specialists identify and address this underlying metabolic impairment.

What Does a Factor XIII Level Test Detect?

The quantitative Factor XIII Level test at Lahore PCR Lab is highly sensitive and capable of detecting a wide spectrum of clinical conditions, physiological states, and pathological abnormalities. Specifically, this specialized assay detects:

• Congenital Factor XIII Deficiency (Severe): Characterized by functional activity levels of less than 1% to 5% of normal, leading to severe hemorrhagic diathesis from early childhood.
• Heterozygous Carrier States: Detects mild, often asymptomatic, reductions in Factor XIII levels (typically 30% to 60% of normal) in family members of affected individuals.
• Acquired Factor XIII Deficiency: Identifies decreased levels resulting from reduced hepatic synthesis in patients with advanced liver cirrhosis or acute liver failure.
• Factor XIII Consumption in DIC: Detects depleted levels of the enzyme due to widespread, systemic activation of the coagulation cascade in Disseminated Intravascular Coagulation.
• Autoimmune Inhibitors of Factor XIII: Identifies the presence of neutralizing autoantibodies directed against the A or B subunits of the Factor XIII molecule, often associated with systemic lupus erythematosus, rheumatoid arthritis, or certain malignancies.
• Inflammatory Bowel Disease (IBD) Activity: Detects decreased Factor XIII levels caused by mucosal consumption and active inflammation in patients with severe Crohn's disease or ulcerative colitis.
• Leukemia-Associated Depletion: Identifies acquired deficiencies associated with acute myeloid leukemia (especially AML-M3) or other hematological malignancies.
• Drug-Induced Factor XIII Reduction: Detects decreased levels associated with the use of certain medications, such as isoniazid, valproic acid, or high-dose chemotherapy.
• Post-Surgical Consumption: Identifies transiently depleted levels following major cardiothoracic, orthopedic, or neurosurgical procedures due to extensive blood loss and consumption.
• Efficacy of Replacement Therapy: Monitors the rise in Factor XIII activity levels following the administration of recombinant Factor XIII, pasteurized Factor XIII concentrates, or fresh frozen plasma.
• Placental Dysfunction Risk: Evaluates the risk of placental abruption or early pregnancy loss in pregnant women with a history of unexplained bleeding.
• Risk of Intracranial Hemorrhage: Assesses the risk of spontaneous intracranial bleeding, which is the leading cause of mortality in patients with severe, untreated Factor XIII deficiency.
• Fibrinolytic Susceptibility: Indirectly detects the vulnerability of a patient's blood clots to rapid degradation by plasmin.
• Normal Coagulation Function: Confirms adequate transglutaminase activity, ruling out Factor XIII deficiency as the cause of a patient's bleeding symptoms.

Turnaround Time and Report Access at Lahore PCR Lab

Because Factor XIII Level testing is a highly specialized coagulation assay requiring precise laboratory techniques and controlled processing, the turnaround time is managed with the utmost efficiency. At Lahore PCR Lab, the standard turnaround time for a quantitative Factor XIII Level test is typically within 24 to 48 hours from the time of sample collection. This timeline ensures that the sample undergoes rigorous double-centrifugation, precise calibration of the automated coagulation analyzer, and thorough clinical validation by a consultant hematologist.

Lahore PCR Lab provides patients and referring physicians with seamless, modern access to diagnostic reports. Once the results are finalized and verified by the laboratory's clinical pathologist, patients receive an automated SMS notification containing a direct link to download their report. Reports can also be accessed securely through the official Lahore PCR Lab online portal or via WhatsApp. For inpatient facilities and consulting hematologists, digital integration allows for immediate electronic medical record (EMR) updates, facilitating prompt clinical decision-making and therapeutic intervention.

Factor XIII Level Findings Overview

Structure / Parameter Evaluated	Normal Findings	Possible Abnormal Findings
Factor XIII Functional Activity	60% to 140% of normal activity	Decreased activity (<60% indicates mild, moderate, or severe deficiency)
Factor XIII A-Subunit Antigen	Within established reference range	Absent or severely reduced in congenital Type II deficiency (catalytic subunit defect)
Factor XIII B-Subunit Antigen	Within established reference range	Reduced in congenital Type I deficiency (carrier protein defect; leads to rapid clearance of A-subunit)
Clot Solubility Screening (Urea/Acid)	Clot remains intact and insoluble for >24 hours	Clot dissolves within 1 to 2 hours (indicates severe deficiency with activity <1-5%)
Prothrombin Time (PT)	Normal (typically 11.0 to 13.5 seconds)	Remains normal in isolated Factor XIII deficiency (helps rule out extrinsic pathway defects)
Activated Partial Thromboplastin Time (aPTT)	Normal (typically 25.0 to 35.0 seconds)	Remains normal in isolated Factor XIII deficiency (helps rule out intrinsic pathway defects)
Thrombin Time (TT)	Normal (typically 12.0 to 16.0 seconds)	Remains normal (rules out quantitative or qualitative fibrinogen abnormalities)
Fibrinogen Concentration	Normal (200 to 400 mg/dL)	Normal (helps differentiate Factor XIII deficiency from severe hypofibrinogenemia)
Platelet Count	Normal (150,000 to 450,000/µL)	Normal (rules out thrombocytopenia as the primary cause of bleeding symptoms)

Note: Diagnostic findings should always be interpreted by a qualified healthcare professional together with the patient's symptoms, medical history, physical examination, laboratory investigations, previous imaging studies, and other relevant clinical information. Additional investigations or specialist consultation may be recommended depending on the findings.

Why Choose Lahore PCR Lab for Factor XIII Level?

• Experienced Healthcare Professionals: Our laboratory is staffed by highly qualified consultant pathologists, clinical hematologists, and experienced laboratory technologists specializing in complex hemostasis testing.
• Patient-Focused Care: We prioritize patient comfort, safety, and clear communication throughout the entire testing process, ensuring a stress-free diagnostic experience.
• Quality Diagnostic Services: Lahore PCR Lab adheres to strict international quality control standards and participates in external quality assurance programs to guarantee the highest accuracy of results.
• Professional Reporting: Every Factor XIII report undergoes a multi-step verification process and is signed off by a consultant hematologist to ensure clinical reliability.
• Modern Diagnostic Approach: We utilize state-of-the-art, automated coagulation analyzers and advanced chromogenic assays to deliver precise quantitative measurements.
• Comfortable Environment: Our collection centers in Lahore are designed to provide a clean, sterile, and welcoming environment for patients of all ages.
• Convenient Location: Strategically located in Lahore, Pakistan, our main laboratory and collection centers are easily accessible to patients from all parts of the city.
• Commitment to Accurate Diagnosis: We understand the critical nature of rare bleeding disorders and are dedicated to providing rapid, precise results that guide life-saving clinical decisions.